Would You like a feature Interview?
All Interviews are 100% FREE of Charge
In recent months, there has been growing interest in using diabetes medications to treat weight loss.
Drugs with brand names such as Ozempic and Wegovy have become very popular among Hollywood celebrities and TikTokers.that led to the whole country shortage for diabetics.
But the anti-obesity drug craze is about to be shaken by another major development. Diabetes drug Munjaro will receive weight-loss approval from the U.S. Food and Drug Administration (FDA) later this year, according to maker Eli Lilly. may receiveThe company just completed a late-stage study of the drug for weight loss and found that participants lost more 50 pounds in almost 17 months.
“We’ve never seen that much weight loss,” said Dr. Nadia Ahmad, Lilly’s medical director of obesity clinical development. CBS news.
Analysts predict that Munjaro, commonly tirzepatide, could become one of the best-selling drugs of all time.Evaluate a pharmaceutical company’s quote as $50 billion in sales by 2028To put this in perspective, Novo Nordisk, which manufactures Ozempic and Wegovy, reports combined sales of around $2.4 billion in 2022.
How does Munjaro work?
Munjaro was approved by the FDA last year for the treatment of type 2 diabetes. The patient takes her one injection per week. The drug works by activating two of her hormones that are naturally produced in the body, reducing appetite and increasing satiety. It also suppresses craving signals that are chemically sent from the gut to the brain.
“Psychologically, you don’t want to eat,” said health tech executive Matthew Barlow. told CBS News“Now you can have two mouthfuls of dessert and be satisfied.”
Although clinical trials have shown the drug to be safe, side effects include nausea and constipation.
Munjaro is not cheap. The monthly dosage can be as high as $1,400. But if the FDA approved it for weight loss, people prescribed it for obesity could be more easily covered by insurance.